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The host immune response to tuberculosis is extremely complex, and in order to fully elucidate 
this, one has to thoroughly study the host response by considering all immune cells and phases of 
infection. T-cells have always been at the forefront of tuberculosis research due to its production 
of interferon-gamma and other pro-inflammatory cytokines. However, our increased 
understanding of B-cells show that these cells display non-humoral functions, such as production 
of cytokines and the expression of death-inducing ligands. These additional functions indicate that 
B-cells have a role to play during infection with Mycobacterium tuberculosis. We hypothesize 
that B-cells utilise these additional functions, like the production of cytokine, to modulate T-cell 
phenotype and function during exposure to Mycobacterium tuberculosis.  
Individuals with newly diagnosed untreated tuberculosis were recruited for the study, and were 
followed up during treatment. Controls recruited included healthy exposed/infected and 
uninfected controls, as well as other lung disease controls. Peripheral blood was collected from 
all these individuals. In order to evaluate B-cell gene regulation, transcriptional analysis was 
performed. Secondly, B-cell phenotypic characterization was done using flow cytometry and 
secreted cytokines evaluated using the Luminex platform. Furthermore, to assess the interaction 
between B- and T-cells, autologous B- and T-cells were co-cultured under various stimulation 
conditions, and the cells and cytokine production (Interferon-gamma, Tumour Necrosis Factor-
alpha and Interleukin-2) analysed using flow cytometry.  
The results indicate that there is decreased activation of B-cells during active tuberculosis, and 
this is restored during anti-TB treatment. Transcriptional and phenotypic analysis show that there 
is a decline in FasL expression by B-cells during tuberculosis (compared to controls), and that the 
expression is enhanced following successful treatment. A potential function underlying FasL 
regulation could involve the induction of apoptosis of infected T-cells as a means to rid the body 
of pathogens. Furthermore, co-culture experiments show that B-cells are able to induce cytokine 
production by both CD4+ and CD8+ T-cells in the context of Mycobacterium tuberculosis 
exposure.  
These results could prove significant as B-cells may serve as a target for new vaccines or modified 
TB treatment. Current interventions are aimed at enhancing T-cell responses in order to combat 
infection. However, if B-cells are able to modulate T-cell responses, then these cells could be used 
to indirectly enhance the T-cell responses needed to eliminate the bacteria. 





Die gasheer immuun reaksie tot tuberkulose is uiters kompleks, en om dit ten volle te verstaan, 
moet 'n deeglike studie van die gasheer reaksie gedoen word deur alle immuunselle en fases van 
infeksie te oorweeg. T-selle was nog altyd aan die voorpunt van tuberkulose navorsing as gevolg 
van die produksie van interferon-gamma en ander pro-inflammatoriese sitokiene. Met ‘n toename 
in ons begrip van B-selle is dit duidelik dat hierdie selle  nie-humorale funksies vertoon, soos 
onder andere die produksie van sitokiene en die uitdrukking van die dood induserende ligande. 
Hierdie bykomende funksies dui aan dat B-selle 'n rol het om te speel gedurende infeksie met 
Mikobakterium tuberkulose. Ons hipotese is dat B-selle hierdie bykomende funksies, soos die 
produksie van sitokiene gebruik, om T-sel fenotipe en funksie te moduleer tydens blootstelling 
aan Mikobakterium tuberkulose. 
Individue met nuut gediagnoseerde onbehandelde tuberkulose was gewerf vir die studie, en is 
opgevolg tydens behandeling. Gesonde kontrole wat blootgestel/besmet is en onbesmette 
kontrole, sowel as kontroles met ander longsiekte was ook gewerf. Perifere bloed is gekollekteer 
vanaf al hierdie individue. Om B-sel geenregulering te evalueer, is transkripsionele analise 
uitgevoer. Tweedens is B-sel fenotipiese karakterisering gedoen met behulp van vloeisitometrie 
en die vlakke van geproduseerde sitokiene geëvalueer met behulp van die Luminex platform. Om 
die interaksie tussen B- en T-selle te bepaal, is hierdie selle in kultuur saamgekweek onder 
verskillende stimulasie kondisies, en die selle en sitokiene produksie (Interferon-gamma, Tumor 
Nekrose Faktor-alfa en Interleukien-2 ) ontleed met behulp van vloeisitometrie. 
Die resultate dui daarop dat die aktivering van B-selle  afneem tydens aktiewe tuberkulose, en dat 
dit  herstel tydens anti-TB behandeling. Transkripsionele en fenotipiese analise toon dat daar 'n 
afname in FasL uitdrukking is deur die B-selle tydens tuberkulose (in vergelyking met die 
kontrole), en dat die uitdrukking  bevorder word na suksesvolle behandeling. 'n Potensiële funksie 
sluit in dat  FasL regulasie  die inlywing van apoptose van besmette T-selle  betrek as 'n manier 
waardeer die liggaam ontslaee raak van patogene. Verder, kwekings eksperimente toon dat B-
selle in staat is om sitokien produksie deur beide CD4+ en CD8 + T-selle in die konteks van 
blootstelling aan Mikobakterium tuberkulose kan verander. 
Hierdie resultate dui aan dat B-selle as 'n teiken vir nuwe entstowwe of TB behandeling kan dien. 
Huidige ingrypings is gemik op die verbetering van T-sel reaksies ten einde infeksie te bekamp. 
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Indien B-selle in staat is om T-sel reaksies te moduleer,  kan hierdie selle gebruik word om die T-
sel reaksie indirek te verbeter om sodoende die bakterieë uit te skakel. 
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Chapter 1. Introduction and Literature review 
 
1.1 Immunology of Tuberculosis 
 
Tuberculosis disease is caused by Mycobacterium tuberculosis (M.tb). The bacteria is spread by 
means of coughing, and the inhalation of sputum droplets which contain the bacteria. Once the 
bacteria are in the airways and lung parenchyma, macrophages and neutrophils are the first cells 
at the site of infection, which then phagocytose and take up the bacilli. The phagocytes (i.e. 
macrophages) recognize pathogen-associated molecular patterns (PAMPs) through toll-like 
receptors which are pattern recognition receptors (PRRs) [1]. This is considered the innate 
immune response. The natural killer (NK) cells migrate to the site of infection where they lyse the 
bacteria directly, as well as the infected macrophages [2], [3]. When neutrophils and macrophages 
undergo apoptosis, the bacilli are released in a contained manner and are taken up by dendritic 
cells (DC). These DC’s then travel to lymph nodes, where it produces interleukin (IL)-12 which 
induces naïve T-cells to become T-helper (Th) 1 cells. The Th1 cells subsequently traffic to the 
lung, where it produces amongst other cytokines, interferon (IFN)-gamma and activates 
macrophages which leads to bacterial control and cytokine production [4]. Mouse studies have 
shown that the production of IFNγ leads to the production of iNOS, which is required to control 
M.tb infection [5], [6]. The interaction with antigen-presenting cells (APC), such as B-cells and 
DCs leads to the adaptive immune response, which comprises of humoral and cell-mediated 
immunity (CMI). B-cells, once activated, induces the humoral immune response by primarily 
producing antibody which assists in fighting invading pathogens. The CMI is essential in the 
control of M.tb infection because it leads to the production of essential pro-inflammatory 
cytokines such as IFNγ, IL2 and tumour necrosis factor (TNF)-α. CMI is initiated when T-cells 
interact with APCs, which leads to activation and production of cytokines and growth factors. 
IFNγ production leads to the recruitment of CD4+ and CD8+ T-cells to the site of infection, and 
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also activates macrophages to kill the bacteria [7]. TNFα is involved in cell migration, as it 
influences the expression of chemokines and chemokine receptors [8]. Therefore TNFα plays a 
role in granuloma formation, which is the aggregation of lymphocytes and macrophages in 
infected tissues in order to contain the bacterial infection. IL2 induces proliferation and expansion 
of antigen-specific lymphocytes [8]. It has been shown that CD4+ Th1 cells are important for 
protection during M.tb infection, and that multi-functional CD4+ T-cells, which produces INFγ, 
TNFα and IL2, correlate with TB disease [9]. Caccamo and colleagues (2010) showed that 
multifunctional CD4+ Th1 cells are detected in 85 to 90% of TB cases, and the frequency of these 
multifunctional T-cells decline after anti-TB treatment [9]. However, the relevance of these 
multifunctional T-cells present during latency or induced by M.tb during TB disease remains 
unclear [10], [11]. 
 
1.2. T-cell activation 
 
T-cells are activated by ligation of the T-cell receptor (TCR) by antigenic peptides in the context 
of Major Histocompatibility Complex (MHC). The TCR may contain either αβ chains (majority), 
which is found on mature T-cells, or the TCR may contain γδ chains [12]. The αβTCR is 
associated with co-receptor molecules, such as CD4 and CD8, which determines the effector 
functions of the T-cells subsequent to activation. These co-receptor molecules also determine 
which cells will present antigenic peptides to the T-cells. More specifically, CD4+ T-cells will 
recognise antigen presented via MHC II, which is expressed by all professional APCs such as 
DCs, B cells and macrophages. Once the TCR of CD4+ T-cells have been engaged, it results in 
signalling pathways that lead to the activation of these cells to become effector T helper (Th) cells 
[13]. T-cells mostly require 2 signals to become activated, one through the TCR and the second 
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through the interaction/binding of co-stimulatory molecules. These Th cells produce various 
cytokines, depending on the antigen and the microenvironment driving the lineage of Th cells 
differentiation. For instance, Th1 cells are induced by IL12 and IFNγ, and in an autocrine fashion 
produce IFNγ, IL2 and TNFα. These cytokines induce pro-inflammatory cell-mediated immunity, 
and also induce the production of opsonizing antibodies by B-cells, which results in the killing of 
invading pathogens. In contrast, Th2 cells are induced by IL4, and produce IL5, IL6, IL4 and IL13 
[14]. These cytokines have an anti-inflammatory effect. In addition to the Th1 and Th2 lineages, 
T-cells may also become Th17 and T-regulatory (Treg) cells, where these cells produce IL17 and 
IL10, respectively. CD8+ T-cells recognise antigen presented by MHC I, which is expressed on 
all nucleated cells. Once activated, CD8+ T-cells will form effector cytotoxic T lymphocytes 
(CTLs), which induce killing of infected cells [15]. This killing activity is induced mainly by the 
release of Granzyme-A and –B, and perforin.  T-cells require co-stimulation for activation, and in 
the same way provide co-stimulation to APCs, such as B-cells, as well. 
 
1.3. B-cell activation and effector functions 
 
B-cells are well known for the production of antibodies which is part of the humoral immune 
responses. B-cells develop from a progenitor in the bone marrow (BM), and enter the periphery 
once it has gone through several developmental stages and forms immature B-cells. B-cells split 
into two major lineages, B1 and B2. The B1 lineage is much less understood, whilst the B2 lineage 
can be further subdivided into follicular (FO), marginal zone (MZ) and transitional (TR), germinal 
centre (GC) and memory B (MB) -cells. The immature cells leave the BM as TR cells, after which 
the B-cells can enter either the FO or MZ subset [16]. Marginal zone cells home to the MZ in the 
splenic white pulp, whereas FO cells recirculate in blood and secondary lymphoid organs. In order 
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for B-cells to be activated it requires two signals, similar to the activation of T-cells. The first 
signal is provided when the B-cell receptor (BCR) is ligated by antigen. The second signal may 
be provided by T-cells (Thymus-dependent (TD)) or through toll-like receptors or via intense 
BCR cross linking (Thymus-independent (TI)) [16]. During TD responses, germinal centres form 
in the lymph nodes and spleen where proliferating B-cells appear at the margins of T-cell zones 
and B-cell follicles. This is where plasma cells (PCs) and MBs arise. PCs produce antibodies, 
which assists in the defence against invading pathogens, but is not sufficient for the control of 
infection[17].  
In addition to the production of antibodies, B-cells are also APCs and studies show that effector 
B-cells and plasma B-cells are also able to produce cytokines [18], [19]. Similar to T-cells, the 
cytokines produced depends on the lineage of cytokine-producing B-cells. In addition, the 
cytokines produced by the B-cells may depend on the local cytokine environment. It has been 
proposed that if the micro-environment contains Th1 cytokines, such as IFNγ and IL2, B-cells 
will form B effector (Be)-1 cells and will produce the Th1-like cytokines. Similarly, if the micro-
environment contains Th2 cytokines, such as IL5 and IL4, Be-2 cells will be induced. B-cells can 
differentiate into regulatory B-cells (Bregs) as well [20]–[22]. These B-cells produce cytokines 
like TGF-β and IL10, and express death inducing ligands like FasL[23]. Furthermore, 
CD19+CD24hiCD38hi Bregs produce cytokine such as IL10 and suppress effector T-cell function 
[24]. A study by Wang and colleagues (2015) indicate that Bregs induce Tregs during gastric 
cancer, and suppress effector T-cells (TEs) (Figure 1.1) [25]. Furthermore,  literature shows that 
this suppression of TEs leads to insufficient bacterial clearance [26], [27]. Prior work from our 
group indicated that B-cells with a plasmablast phenotype (CD138+) produced the majority of 
cytokines secreted in response to stimulation with BCG and TLR9-agonist [28]. Similarly, a study 
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on parasites found that IL17-producing plasmablasts played an important role in combating 
disease pathology [29].  
 
 
Figure 1.1. Effects of Bregs on Tregs and Effector T-cells during gastric cancer 
The frequency of regulatory B-cells is increased during gastric cancer, which induces Tregs and suppresses 
effector T-cell function by means of IL10 production. These Treg cells, in turn, have a suppressive effect 
on tumour cells [25].  
 
1.4. Relationship between B- and T-cells 
 
As mentioned above, in order for T-cells to become activated, two signals are required. The first 
signal is provided by the binding of MHC/peptide complex to the TCR and CD4/CD8 co-receptor. 
The second co-stimulatory signal, is provided by the binding of CD80 or CD86, which is 
expressed on the APC to CD28 expressed on the T-cells [12]. In the case of B-cells acting as APC, 
MHC II/peptide complex binds to the TCR and CD4 co-receptor. In addition to this, T-cells 
provide a co-stimulatory signal to the APC (B-cells) by the binding of CD40L expressed by T-
cells to CD40 expressed by APC (B-cells). This co-stimulation increase the expression of MHC 
by the APCs, as well as co-stimulatory receptors. However, what remains unclear is the extent of 
the relationship between B- and T-cells during immune activation and infection with M.tb. 
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Due to the additional effector functions of B-cells, namely APC and the production of cytokines, 
B-cells have the potential to modulate T-cell behaviour. Cytokines produced by B-cells may 
induce different effector T-cells (Figure 1.2). For instance, Be-1 cells may have the potential to 
induce Th1 cells. Similarly, if Be cells produce Th2-like cytokines (Be-2 cells), it may induce 
naïve T-cells to become Th2 cells. This is an important hypothesis to explore due to the significant 
role assigned to T-cells during TB. In addition to the production of cytokine and presenting 
antigen to T-cells, B-cells have the potential to induce cell death by expressing death ligands [23]. 
Studies show that a small subset of regulatory B-cells express Fas-Ligand (FasL) [23]. FasL 
(CD178) induces cell death once it binds to Fas (CD95) on the surface of target cells. Evidence 
show that B-cells expressing FasL has the potential to induce apoptosis of CD4+ T-cells [30]. 
These studies were focussed on autoimmunity, however evidence exists that indicate that B-cells 
may behave similarly during TB disease, where this phenotype was shown to be induced when 




Considering the current literature, we hypothesize that B-cells utilise alternative effector functions 
during TB disease which may play an essential role in the host defence against infection, such as 
the production of cytokine or the expression of regulatory factors. Furthermore, we hypothesize 
that B-cells play an important role in the modulation of T-cell responses to invading pathogens.   
 




Figure 1.2. Proposed relationship between cytokine-producing B-cells and T-cells 
Cytokines produced by Be1 cells (IFNγ) induce naïve T-cells to differentiate into Th1 cells, which then 
produce cytokine that maintain Be1 cells. Similarly, Be2 cells produce cytokine (IL4) that induce naïve T-




1.6 Aims and Objectives 
 
With this study we aimed to evaluate the B-cell behaviour during M.tb infection, and how anti-
TB treatment affects B-cell non-humoral responses. We also investigated how B-cells modulate 
T-cell profiles and subsequent responses.  
The first objective was to evaluate the B-cell gene regulation during M.tb infection and TB 
treatment by means of transcriptomic analyses (Chapter 2). Secondly, by means of flow cytometry 
we characterised the phenotype of B-cells present during TB disease and how these cells are 
affected during anti-TB treatment (Chapter 3). Finally, we were interested in how B-cells shape 
the T-cell phenotype following co-culture under varying conditions to elucidate the role of B-cells 
during T-cell modulation (Chapter 4).  
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Activated B-cells increase T-cell behaviour during autoimmune disease and other infections by 
means of cytokine production and antigen-presentation. Functional studies in experimental 
autoimmune encephalomyelitis (EAE) indicate that B-cell deficiencies, and a lack of IL10 and 
IL35 leads to a poor prognosis. We hypothesised that B-cells play a role during tuberculosis. We 
evaluated B-cell mRNA expression using real-time PCR from healthy community controls, 
individuals with other lung diseases and newly diagnosed untreated pulmonary TB patients at 
three different time points (diagnosis, month 2 and 6 of treatment).  
We show that FASLG, IL5RA, CD38 and IL4 expression was lower in B-cells from TB cases 
compared to healthy controls. The changes in expression levels of CD38 may be due to a reduced 
activation of B-cells from TB cases at diagnosis. By month 2 of treatment, there was a significant 
increase in the expression of APRIL and IL5RA in TB cases. Furthermore, after 6 months of 
treatment, APRIL, FASLG, IL5RA and CD19 were upregulated in B-cells from TB cases. The 
increase in the expression of APRIL and CD19 suggests that there may be restored activation of 
B-cells following anti-TB treatment. The upregulation of FASLG and IL5RA indicates that B-cells 
expressing regulatory genes may play an important role in the protective immunity against M.tb 
infection. Our results show that increased activation of B-cells is present following successful TB 
treatment, and that the expression of FASLG and IL5RA could potentially be utilised as a signature 
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2.2. Introduction  
 
T-cell driven cell-mediated immunity, have been the focus of studies investigating host immunity 
against M.tb infection [35]–[37] and TB disease. However, an increasing number of studies are 
indicating that the role of B-cells in the protective immunity against M.tb infection has been 
underestimated. B-cells are the key players during humoral immunity and produce antibodies in 
response to invading pathogens. Studies found that humoral immunity may enhance protection 
against M.tb infection [38]–[40]. Furthermore, B-cells have additional functions that may be 
essential for host protection during infection and disease. Activated B-cells change T-cell 
behaviour during autoimmune disease and other pathogenic infections by means of cytokine 
production and antigen-presentation. Effector B-cells can either produce IFNγ and IL12 (Be-1 
cells) or IL2, IL13 and IL4 (Be-2 cells) depending on whether the cells are primed by Th1 or Th2 
cells, respectively [41], [42]. These cytokine-producing effector B-cells are able to amplify T-cell 
responses in a cytokine-dependent manner [43], [44].  
B-cells also display regulatory phenotypes, which secrete IL10, IL35, and express FAS ligand 
(FasL). Functional studies in Experimental autoimmune encephalomyelitis (EAE) indicate that B-
cell deficiencies, and a lack of IL10 and IL35 lead to a poor prognosis[45]. B-cells limited EAE 
pathogenesis by means of IL35 secretion, which decreased the accumulation of pathogenic cells 
in the target organ. FasL-expressing B-cells have a similar effect during autoimmune disease. 
These B-cells induce apoptosis of CD4+ T-cells, have the potential to reduce the inflammatory 
responses during autoimmune disease and are induced by IL5 [46]. High levels of FasL expression 
was observed in B-cells activated via the Toll-Like Receptor (TLR) 9  agonist CpG [47]. We 
hypothesised that B-cells play a similar role during tuberculosis disease. Transcriptional 
approaches are useful for the discovery of biomarkers for the diagnosis and measurement of 
treatment response [48]–[51]. We evaluated patterns in the expression of B-cell genes to better 
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our understanding of B-cell behaviour during M.tb infection and tuberculosis (TB). Real-time 
PCR was utilised to assess the expression of gene transcripts of cytokines, together with genes 
involved in B-cell activation and effector functions. 
 
2.3. Materials and Methods 
2.3.1. Participant recruitment and Sample collection 
 
This study was carried out according to the Helsinki Declaration and International Conference of 
Harmonisation guidelines. All participants provided written informed consent for participation in 
the study, and the use and storage of the samples for biomarker discovery. Ethical approval was 
obtained from the Health Research Ethics Committee (Ethics number N10/01/013) of 
Stellenbosch University and the Departments of Health of the Province of the Western Cape and 
City of Cape Town. 
 
The study participants were recruited from the Ravensmead/Uitsig community in Cape Town 
Western Cape. Individuals with newly diagnosed, untreated pulmonary TB were enrolled into the 
study prior to commencement of anti-TB treatment. The inclusion criteria for the ten healthy 
controls was a positive QuantiFERON (QFN) test. For TB cases we included participants with a 
chest radiograph with suggestive signs of TB, clinical symptoms of TB including a chronic cough, 
weight loss and night sweats, as well as a positive sputum-culture and -smear. The exclusion 
criteria included prior cases of TB or other lung diseases, and an HIV positive status. In addition, 
ten individuals with a lung disease (other than TB) were enrolled into the study.  Half of the other 
lung disease (OLDs) (Table 2.1) were QFN positive. The individuals in the OLD and healthy 
control (Ctrl) groups did not present any clinical symptoms of M.tb infection.  
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Peripheral blood was collected from the study participants into sodium heparin tubes, as well as 
sputum samples for smear/culture tests. The individuals with TB were subsequently followed up 
at month two and month six of treatment, where blood and sputum samples were collected once 
more to monitor their response to treatment. Thirteen TB cases had converted to culture negative 
at month 2 of treatment, and all TB cases were cured at the end of treatment which was confirmed 
by sputum culture tests.  
 
Table 2.1. Clinical and demographic characteristics of study participants 
 TB CTRL OLD 
No. of Female  8 10 5 
No. of Male  12 0 5 
QuantiFERON status (Dx) NA POSITIVE 5 POSITIVE 
5 NEGATIVE 
Sputum-culture status (Dx) POSITIVE NEGATIVE NEGATIVE 
 
 
2.3.2. Sample preparation, mRNA isolation and Quality Check  
 
On the day of blood collection, peripheral blood mononuclear cells (PBMCs) were isolated using 
the ficoll/histopaque separation method (GE Health, Piscataway, NJ). Total B-cells were isolated 
using the MACS bead separation method through positive selection (B cell isolation kit II, 
Miltenyi, Germany), and stored in RNAlater® (Life Technologies, USA). The cells were stored 
in liquid nitrogen until batch analysis.  
The cells were thawed on ice and spun down before being washed in Phosphate-buffered saline 
(PBS). Subsequently, mRNA was isolated using the RNEasy® Mini Kit (Qiagen, Germany) 
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according to manufacturer’s instructions. RNA purity and quantification was assessed using 
NanoDrop 2000 spectrophotometer data. More specifically, the 260/ 280 ratio and the 260/ 230 
ratio were measured to assess the purity of the isolated RNA. A 260/280 and 260/230 ratio of at 
least 1.7 and 1.5 respectively, was considered sufficiently pure for further analysis. The RNA 
samples were stored at -80 ˚C. 
 
2.3.3. cDNA synthesis and RT-qPCR 
 
The isolated RNA was thawed on ice and diluted to a concentration of 300ug, and subsequently 
used to synthesise cDNA. The procedure was carried out in a thermal cycler (Life Technologies, 
USA) using the First Strand Kit (Qiagen, Germany) according to the manufacturer’s instructions. 
The cDNA was then used as template for quantitative PCR on the ABI 7900HT platform. The 
RT2 Profiler Custom Arrays (Qiagen, Germany) were utilised and manufacturer’s instructions 
were followed. The arrays contained primers for the following genes of interest: IL35 
(NM_000882.3), IL4(NM_000589.3), Fas-ligand (FASLG) (NM000639.2), IL5RA receptor alpha 
(IL5RA) (NM_000564.4), cluster of differentiation 38 (CD38) (NM_001775.2), APRIL 
(NM_00198622.1), BAFF (NM001145645.2), TNF-a (NM_000594.3),  Fc gamma receptor 1 
alpha (FCGR1A) (NM_000566.3), Toll-like receptor 9 (TLR9) (NM_017442.3), STAT6 
(NM_001178078.1), as well as two housekeeping genes B2M (NM_004048) and GAPDH 
(NM_002046). FASLG, IL5RA and IL35 is associated with regulatory B-cells. Furthermore, 
APRIL, CD38 and TLR9 is involved in B-cells activation.  
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2.3.4. Data Analysis 
 
The gene expression data obtained from the ABI 7900HT was represented as Ct values, which 
indicated the earliest visible cycle of amplification. These Ct values were converted to fold change 
values using the Qiagen online software (www.SABiosciences.com/pcrarraydataanalysis.php). 
Where applicable, differences were calculated using Prism 5 Software and Kruskal-Wallis tests, 
where p < 0.05 indicates a statistically significant difference. Heatmaps were generated using delta 
Ct (dCt) data and R statistical packages. 
 
2.4. Results 
2.4.1. Comparison of gene expression between TB, OLD and Control groups 
 
In order to evaluate the differences in the expression of the 12 B-cell specific genes between 
healthy controls (Ctrl), TB cases and individuals with other lung diseases (OLD), the delta Ct 
method was utilised. All analyses were carried out by means of the online software provided by 
SABiosciences.  
The expression of APRIL, BAFF, CD19, IL4, FCGR1A, IL35, IL5RA, TNF and TLR9 was similar 
between Ctrl and OLD groups (p>0.05, Table 2.2). In contrast, FASLG and CD38 expression was 
significantly decreased in OLD compared to Ctrl (p<0.01; Table 2.2). There were no differences 
in the expression of all the genes between individuals with other lung diseases and TB cases (Table 
2.2). When comparing the expression of the genes between healthy controls and TB cases, we 
found that there was a significant decrease in the expression of IL4, FASLG, IL5RA and CD38 
(p<0.05) (Table 2.2). The relative gene expression changes between the CTRL, OLD and TB 
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groups are shown in in the form of a heat map (Figure 2.1), which demonstrates differential 
expression of genes between the control group and the TB group is evident. 
 
Table 2.2. Gene expression differences between TB and Control Groups 
The fold change values represent the changes in gene expression between the respective groups, as 
calculated by SABiosciences online software. Positive values indicate an increase in expression, (negative 
value indicates a decrease in expression) between groups. Kruskal-Wallis tests were used for comparisons, 












APRIL  -2.08  p > 0.05  -3.03  p > 0.05 -1.46   p > 0.05 
TLR9  -1.60  p > 0.05  -2.10  p > 0.05  -1.31  p > 0.05 
IL5RA  -3.54  p > 0.05  -8.26 p < 0.01  -2.33  p > 0.05 
IL4  -7.03  p > 0.05  -10.70 p < 0.01  -1.52  p > 0.05 
IL35  -2.77  p > 0.05  -3.35  p > 0.05 
  
 -1.21  p > 0.05 
FASLG  -6.26 p < 0.01  -5.70 p < 0.01  1.10  p > 0.05 
FCGR1A  -1.78  p > 0.05  1.39  p > 0.05  2.47  p > 0.05 
BAFF  -1.71  p > 0.05  -1.74  p > 0.05  -1.02  p > 0.05 
TNF  1.63 p < 0.05 
  
 1.12  p > 0.05  -1.45  p > 0.05 
CD38  -6.06 p < 0.01   -6.59 p < 0.01  -1.09  p > 0.05 
CD19  1.08  p > 0.05  -1.03  p > 0.05  -1.12  p > 0.05 
STAT6  -1.57  p > 0.05  -1.66  p > 0.05  -1.06  p > 0.05 
 
 




Figure 2.1. Differences in mRNA expression between TB and Control groups 
Comparison of the average gene expression between the respective groups. Where Ctrl are healthy controls, 
OLD are individuals with other lung diseases and TB are individuals is TB disease. Heatmap, which was 
generated using R statistical packages, depicting changes in relative gene expression (dCt). Genes with 
low expression levels are depicted in yellow, whereas genes with high expression levels are depicted in 
blue.  
 
2.4.2. Differential gene expression during Anti-TB treatment 
 
The expression of the B-cell specific genes was compared between diagnosis (before treatment 
started), month two (the time point frequently used to evaluate  sputum culture conversion) and 
month six (end of treatment) following the initiation of anti-TB treatment. There were no 
significant differences in the expression of BAFF, CD19, FASLG, IL4, CD38, FCGR1A, IL35, 
TNF and TLR9 between diagnosis and month 2 of treatment (p>0.05) (Table 2.3). However, 
APRIL and IL5RA were differentially expressed between these two time points with fold changes 
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Table 2.3. Gene expression in TB group over 6 months of treatment 
The fold change values represent the changes in gene expression between the respective groups, as 
calculated by SABiosciences online software. Positive values indicate an increase in expression, whereas 
a negative value indicates a decrease in expression. Kruskal Wallis tests were used for comparisons, and a 









p-value  Fold 
Change 
p-value 
APRIL 1.85 p < 0.05 2.06 p < 0.01 1.12 p > 0.05 
IL5RA 1.87 p < 0.05 1.96 p < 0.05 1.05 p > 0.05 
TLR9 1.18 p > 0.05 1.35 p > 0.05 1.15 p > 0.05 
IL4 1.79 p > 0.05 1.84 p > 0.05 1.03 p > 0.05 
IL35 1.04 p > 0.05 1.21 p > 0.05 1.17 p > 0.05 
FASLG 1.33 p > 0.05 1.87 p < 0.01 1.40 p > 0.05 
FCGR1A -1.91 p > 0.05 -2.74 p > 0.05 -1.43 p > 0.05 
BAFF 1.13 p > 0.05 1.00 p > 0.05 -1.12 p > 0.05 
TNF 1.10 p > 0.05 -1.02 p > 0.05 -1.12 p > 0.05 
CD38 1.65 p > 0.05 1.48 p > 0.05 1.11 p > 0.05 
CD19 1.49 p > 0.05 1.77 p < 0.05 1.18 p > 0.05 
STAT6 1.08 p > 0.05 1.21 p > 0.05 
 
1.12 p > 0.05 
 
 
When comparing the expression of the 12 genes between diagnosis and month six of treatment, 
APRIL, CD19, FASL and IL5RA were differentially expressed (Table 2.3 and Figure 2.2). There 
was an increase in the expression of all the latter genes at month 6. The expression of BAFF, 
STAT6, IL35, TNF, CD38 and TLR9 was similar at diagnosis and month six of treatment. The 
relative gene expression is depicted in a heat map (Figure 2.3)  
 


















































































































Figure 2.2. Genes differentially expressed during anti-TB treatment 
Relative expression of genes as calculated using the dCt method (Ct (gene) – Ct (housekeeping gene)). 
Statistical differences calculated by means of Kruskal Wallis tests, where significant differences are 
indicated by an asterisk (* = p <0, 05 or ** = p<0.01). Data represented as median dCt with bars 
representing range. High dCt values indicate low gene expression, and low dCt values indicate high gene 















Figure 2.3. Differential mRNA expression over the course of anti-TB treatment 
Heat map depicting changes in relative gene expression (dCt). Genes with low expression levels are 
depicted in yellow, whereas genes with high expression levels are depicted in blue. (a) Comparison of the 
average gene expression between the respective groups. (b) Group comparisons showing gene expression 
for individual participants.  





B-cells displaying regulatory phenotypes secrete cytokines such as IL10 and IL35, and also 
express FasL. These FasL-expressing B-cells have predominantly been studied in autoimmune 
diseases and infections [52]. A study conducted in mice showed that IL35 secreted by B-cells 
limited EAE pathogenesis by decreasing the accumulation of pathogenic cells in the target organ 
[45]. Similarly, B-cell-deficiencies in mice have been linked to a decreased control of Salmonella 
infection [53]. In the current study, FASLG, IL5RA and IL4 expression were decreased in TB cases 
at diagnosis compared to healthy controls. In contrast, FASLG and IL5RA expression were 
increased after 6 months in TB cases. These results suggest that B-cell activity may be restored 
following successful anti-TB treatment and could play a role in the protective immunity against 
M.tb infection.  
CD38 is a membrane-bound protein which is expressed on the surface of B-cells throughout their 
lifespan [54]. However, the expression of CD38 is highest on B1 B-cells [55]. Crosslinking of the 
CD38 receptor on mature B-cells leads to proliferation, isotype switching and reduced apoptosis. 
Additionally, CD38 acts as a co-stimulatory signal to B-cells activated by means of TLR ligands 
[56], [57]. Here we show a decline in the expression of CD38 in B-cells from TB participants 
compared to healthy controls. This points to a reduction in the activation of B-cells during active 
M.tb infection. APRIL, which is a proliferation inducing ligand, is also associated with the 
activation of B-cells. We found APRIL at lower levels in TB participants compared to healthy 
controls. However, the expression of this gene was restored after 6 months of treatment, in 
addition to CD19. Together these results suggest that there is an increase in B-cell activation 
throughout treatment in TB cases. This restored B-cell activation may lead to more interactions 
between B-cells and helper T-cells due to the upregulation of co-stimulatory molecules [57].  
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Transcriptional analyses are useful for the identification of biomarkers for diagnostics, as well as 
monitoring treatment response during tuberculosis and other diseases [48]–[51]. In the current 
study, FASLG and IL5RA was downregulated in TB cases at diagnosis compared to healthy 
controls. The expression of the latter genes were upregulated in TB cases at 6 months of treatment. 
Collectively, this suggests that FASLG and IL5RA have the potential to be utilised as a 
biosignature to monitor success or failure of treatment. Further studies in larger cohorts are 
required to confirm this.  
In conclusion, the results of our pilot study suggest that B-cells expressing regulatory genes could 
be involved during the immune response to M.tb infection. Previous studies of regulatory B-cells 
focussed mostly on autoimmune diseases and helminth infections. Supplementary transcriptional 
and functional studies are required to confirm the precise role that B cells play during tuberculosis 
disease and the mechanisms by which the activation/immune induction is achieved.  
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Chapter 3. B-cells with a FasL expressing regulatory phenotype are induced 




Studies show that B-cells, in addition to producing antibodies and antigen-presentation, are able 
to produce cytokines as well. These include regulatory cytokines such as IL-10 by regulatory B-
cells. Furthermore, a rare regulatory subset of B-cells have the potential to express FasL, which 
is a death-inducing ligand. This subset of B-cells have a positive role during autoimmune disease, 
but has not yet been studied during tuberculosis. These FasL-expressing B-cells are induced by 
bacterial LPS and CpG, thus we hypothesised that this phenotype might be induced during 
tuberculosis as well.  
B-cells from participants with TB (at diagnosis and during treatment) and controls were collected, 
and analysed by means of real-time PCR and flow cytometry. In addition to this, BAL was 
collected from TB participants as well and analysed by means of MAGPix (multi-cytokine) 
technology.  
Gene expression analysis show that FASL transcript levels increase by the end of treatment. 
Similarly, phenotypic analysis show that there is a higher frequency of FasL-expressing B-cells 
by the end of treatment.   
Collectively, these results indicate that these FasL-expressing B-cells are being induced during 









B lymphocytes (B-cells) are predominantly recognised for its role during humoral immunity, 
whereby they produce antibody to assist in fighting infections. However, B-cells are able to 
produce cytokine as well, and the type of cytokines produced is dependent on the 
microenvironment. Effector type 1 B-cells (Be-1) produce Th1 type cytokines such as IFNγ and 
TNFα, Be-2 cells produce Th2 type cytokines while regulatory B-cells produce IL10 [20]. 
Cytokine-producing B-cells play important roles in the regulation of immunity and have been 
extensively studied in the context of autoimmune disease [20], [58]. B-cell culture studies have 
shown that there is a balance in the proinflammatory and regulatory responses of B-cells [59]–
[61]. In the context of autoimmune disease, and more specifically multiple sclerosis (MS), this 
balance is skewed toward a more proinflammatory response due to a reduction in the production 
of IL10 [58]. The balance is however restored upon treatment. An additional regulatory function 
utilised by B-cells is the expression of Fas-Ligand (FasL) upon activation [62], [63]. This subset 
of B-cells is rare and has been studied in the context of autoimmune disease as well as helminth 
infections [64]. These regulatory “killer” B-cells are CD19+IgM+ and induce apoptosis of CD4 T-
cells, and thus have a positive effect during autoimmune disease. The B-cells induce FasL-
mediated apoptosis of autoreactive T-cells, thereby regulating/reducing the inflammation. Klinker 
and colleagues (2013) showed that this regulatory subset of B-cells are induced by IL5, and that 
there is an increase in the expression of IL5 receptor alpha (IL5Rα) [64]. Lymphocytes may 
undergo exhaustion due to persistent infections and prolonged activation. This occurs as the cells 
fail to response to antigenic challenge, and has increased expression of markers of exhaustion 
such as programmed cell death protein (PD) 1. The role of these ‘killer’ B-cells during 
tuberculosis has not yet been studied, but it was shown that this phenotype is induced in B-cells 
upon stimulation with TLR9 agonist CpG [47]. This may imply that the same regulatory 
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phenotype could be induced in the context of TB, as B-cell TLR9 is triggered by mycobacterial 
CpG motifs [1], [31], [33], [34]. Thus, we hypothesised that FasL expression in B-cells is induced 
during M.tb infection. We therefore aimed to evaluate gene expression patterns of FASL and 
IL5RA by B-cells using real-time PCR. Additionally, we aimed to evaluate the phenotype of B-
cells from individuals with TB by means of flow cytometry, and how this changes throughout 
treatment. Finally, we evaluated host marker levels in BAL and plasma from individuals with TB.   
 
3.3. Materials and Methods 
 
3.3.1. Ethics Statement 
Ethical approval was obtained from the ethics committee of Stellenbosch University (N10/01/013 
78 and N13/05/064) and the City of Cape Town City Health. The study was conducted according 
to the Helsinki Declaration and International Conference of Harmonisation guidelines. Written 
informed consent was obtained from all study participants. 
 
3.3.2. Participant recruitment 
All participants were recruited in Ravensmead/Uitsig Community in Cape Town. Newly 
diagnosed TB were recruited for the study before initiation of treatment. The inclusion criteria is 
shown in table 1. The TB cases were followed up during the course of 6 month treatment. In 
addition, healthy controls (CTRL) and individuals with other lung diseases (OLD) including 
pneumonia, asthma exacerbations, pleuritis and chronic obstructive pulmonary disease (COPD) 
were recruited. The healthy controls were all QuantiFERON (QFN) positive, which is indicative 
of latent TB infection (LTBI).  Participants with cancer were included in the study as controls for 
the bronchoscopies (Addendum A). These participants displayed respiratory symptoms due to 
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inflammatory or infective cause, but were sputum-culture and Gene Xpert negative, which 
indicated that they did not have TB.  Individuals who had recently completed TB treatment (within 
3 months) and were sputum-culture negative were selected for bronchoscopies. Bronchoscopies 
were performed at Tygerberg Hospital, Cape Town, and transported to the laboratory under 
controlled conditions for processing.  
 
Table 3.2. Inclusion and Exclusion criteria for participant recruitment 
* cough, fever, night sweats, weight loss, loss of appetite  
 
 
3.3.3. B-cell phenotype analysis using Flow cytometric analysis 
One ml of sodium heparin blood was collected from 13 CTRLs (once-off) and 13 TB cases at 
diagnosis, week 2, month 1 and month 6 of treatment. The blood was lysed using 1x BD 
fluorescence-activated cell sorter (FACS) Lysing solution (BD, New Jersey, USA), and the 
leukocytes were cryopreserved in fetal calf serum (FCS, BIOCOM Biotech) containing 10% 
DMSO (Sigma, Missouri, US), placed in a Mr. Frosty at -80˚C overnight and transferred to liquid 
nitrogen the following day. 
Once all the samples had been collected, cells were retrieved from liquid nitrogen and washed in 
FACS buffer (PBS containing 2% FCS). The cells were then stained for 30 minutes with the 
TB CTRL OLD 
 Clinical signs of TB* 
 Chest radiographs with 
sign of TB 
 Positive sputum 
culture test 
 HIV negative 
 No clinical signs of 
TB* 
 Chest radiographs 
with no signs of TB 
 Negative sputum 
culture test 
 QFN positive 
 HIV negative 
 No clinical signs of 
TB* 
 Negative sputum tests 
 No prior or current TB 
 HIV negative 
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following antibodies; CD19-BV510, IgM-FITC, CD125w (or IL5RA)-PE, CD3-PerCP, PD1-
BV421, CD40-APC-H7, CD38-PE-Cy7 and CD178 (or FASL)-APC. Subsequently, the samples 
were analysed using the FACS Canto II (BD) and the data was analysed using FlowJo software 
(Version 10, Oregon, US).  
 
3.3.4. B-cell gene expression analysis 
 
Blood was collected into sodium heparin tubes from 10 CTRLs and 10 OLD (once-off), and 19 
TB cases at diagnosis, month 2 and month 6 of treatment, and peripheral blood mononuclear cells 
(PBMCs) were isolated using the ficol-histopaque (Sigma-Aldrich, Missouri, US) separation 
method. Subsequently, total B-cells were isolated from the PBMCs by positive selection using the 
B-cell MACS Isolation kit (Miltenyi) according to the manufacturer’s instructions. Cell purities 
were checked by flow cytometry and were above 90%. 
RNA was isolated from these B-cells and used to synthesise cDNA. The procedure was carried 
out in a thermal cycler (Life Technologies, California, USA) using the First Strand Kit (Qiagen, 
Hilden, Germany) according to the manufacturer’s instructions. Quantitative PCR was carried out 
using the ABI 7900HT platform (Applied Biosystems, California, US). The RT2 Profiler Custom 
Arrays (Qiagen, Hilden, Germany) were utilised and manufacturer’s instructions were followed. 
The arrays contained primers for Fas-ligand (FASLG) (NM000639.2) and IL5RA receptor alpha 
(IL5RA) (NM_000564.4) which are genes associated with regulatory FasL-expressing B-cells. 
The gene expression data obtained from the ABI 7900HT was represented as Ct values, which 
indicated the earliest visible cycle of amplification. These Ct values were converted to fold change 
values using the Qiagen online software (www.SABiosciences.com/pcrarraydataanalysis.php).  
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3.3.5. Host marker detection in BAL and PLASMA using LUMINEX platform 
 
Bronchoscopies were performed on 20 TB patients at diagnosis and at the end of treatment. During 
the procedure, bronchoalveolar lavage (BAL) was collected by washing the lung interior with 
saline. The BAL samples were spun down and the supernatants were used for protein analysis. In 
addition, blood was collected from these individuals into EDTA tubes and centrifuged in order to 
collect plasma. Bronchoscopies were also performed on 10 individuals with lung cancer, to serve 
as a control group. A custom Human CD8+ T-cell Magnetic Bead Panel Kit 
(HCD8MAG15K17PMX, Merck Millipore, St. Charles, Missouri, USA) was utilised to evaluate 
the levels of the following six host markers; Granzyme A, Granzyme B, Perforin, soluble Fas 
Ligand (sFasL), IL5 and Granulocyte macrophage colony stimulating factor (GM-CSF). The 
assay was carried out according the manufacturer’s instructions and the concentration of the 
marker measured on the MAGPix platform (Bio-Rad Laboratories, California, US). Two quality 
controls included in the kit were run in duplicate. Levels of all analytes in the quality controls 
were within the expected ranges. A standard curve ranging from 0.08 to 1.7 pg/ul was used for 
GM-CSF, 0.93 to 19 pg/ul for Granzyme A, 0.04 to 0.85 pg/ul for Granzyme B, 0.03 to 0.67 pg/ul 
for IL-5, 0.27 to 6.0 pg/ul for sFasL, and 0.24 to 5.6 pg/ul for Perforin. Bio-Plex Manager 
software, version 6.1 (California, US), was used to analyse the data.   
 
3.3.6. Statistical analysis 
Statistical analysis was carried out using Graph Pad Prism 5 Software (San Diego, CA).Where 
applicable, differences between groups were calculated using Student t-test, one-way ANOVA 
and Dunn’s multiple comparison post-hoc tests. Significant differences are indicated by p<0.05. 
 





3.4.1. Activated B-cells express a FasL+IL5Ra+ phenotype following anti-TB treatment 
 
Seeing that the regulatory “killer” B-cells express CD178 (FASL) and studies have shown that 
there is an increased expression of IL5RA on these cells, we were interested in the expression of 
FASL (CD178) and IL5RA (CD125) on B-cells. Additionally, we were interested in the 
expression of PD1 and CD40 as well, as increased PD1 and CD40 expression is linked to cell 
exhaustion. To evaluate the expression of the surface markers, the gating strategy shown in Figure 
3.1 was followed. When comparing the frequency of CD19+ IgM+CD38+ cells expressing FASL 
(CD178) and IL5RA (CD125) between CTRLs and TB cases, there were no significant 
differences between the two groups (Figure 3.2 a). There was, however, a trend that the expression 
of FASL (CD178, p=0.06), was higher in CTRLs when compared to TB cases. When comparing 
the frequency CD19+ IgM-CD38+ cells expressing FASL/CD178 and IL5RA/CD125, we found 
that there was a significant difference in the frequency of IL5RA between CTRL and TB groups 
(p= 0.03; Figure 3.2b). There were no significant differences in frequency of CD19+ IgM+CD38+ 
and CD19+ IgM-CD38+ expressing CD40 and PD1 (Figure 3.2 c and d). 
There was, also, however a trend in that the expression of CD40 by IgM- B-cells, was higher in 
CTRLs (p=0.06). Overall, the expression of FASL/CD178 and IL5RA/CD125, as well as CD40 
and PD1 was higher in CTRLs compared to TB participants (Figure 3.2), even though these 
differences were not statistically significant. 
 




Figure 3.1. The Gating strategy used to identify B-cells of interest 
All single cells were selected to exclude doublets, and subsequently lymphocytes were gated on SSC and 
FSC. CD3-CD19+ cells were then gated to select B-cells. Furthermore IgM- and IgM+ B-cells were gated 
and assessed CD178/IL5RA and PD1/CD40 expression.  
 
3.4.2. Effects of anti-TB treatment on the expression of Regulatory and exhaustion 
markers by B-cells 
 
The frequency of CD19+IgM+CD38+ and CD19+IgM-CD38+ cells expressing FASL/CD178 and 
IL5RA/CD125, as well as CD40 and PD1 were evaluated during the course of 6-month TB 
treatment in order to assess the effects of treatment. The frequency of CD19+IgM+CD38+ of cells 
expressing FASL/CD178 (CD178+IL5RA-) decreased during treatment, whereas the expression 
of IL5RA/CD125 (CD178-IL5RA+) increased during treatment (Figure 3.3a). Furthermore, the 
frequency of cells expressing both FASL/CD178 and IL5RA/CD125 (CD178+IL5RA+) was 
higher at week 2 and month 6 of treatment compared to diagnosis (Figure 3.3a). These changes 
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were however not statistically significant. The frequency of CD19+IgM-CD38+ cells expressing 
FASL/CD178 decreased by month 6 of treatment, however expression was highest at month 1 of 











































































































































 B-cells expressing FASL (CD178)/IL5Ra (CD125) and 
CD40/PD1 between TB cases and CTRLs 
CD19+ B-cells acquired by means of Flow cytometry. Differences in frequency of cells expressing 
regulatory and exhaustion markers calculated using one-way ANOVA tests and Dunn’s multiple 
comparison post-hoc tests. Significant differences are indicated by an asterisk (*), where p<0.05 (a) IgM+ 
B-cells expressing FASL/CD178 and IL5RA/CD125 (b) IgM- B-cells expressing FASL/CD178 and 
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The expression of IL5RA/CD125 increased by the end of treatment, but was lowest at month 1 of 
treatment. (Figure 3.3b). Additionally, the frequency of cells expressing FASL/CD178 and 
IL5RA/CD125 (CD178+IL5RA+) was higher at month 1 and month 6 of treatment compared to 
diagnosis. These changes, however, were not statistically significant either.  
The expression of CD40 and PD1 by CD19+IgM+CD38+ and CD19+IgM-CD38+ cells were 
evaluated as well (Figure 3.4). The frequency of IgM+ and IgM- B-cells expressing CD40 
(CD40+PD1-) increased during treatment, with the increase being more apparent in the IgM+ 
population, while the frequency of PD1 expressing (CD40-PD1+) B-cells decreased (Figure 3.4a 
and 3.4b). The frequency of IgM- B-cells expressing both CD40 and PD1 (CD40+PD1+) was 














Figure 3.3. Frequencies of Regulatory B-cells expressing CD178 and IL5A during treatment 
Pie charts depict frequencies of B-cells expressing either CD178, IL5RA or both simultaneously in TB 
participants during treatment. Where BL is diagnosis, W2 is week 2, M1 is month1 and M6 is month 6 of 
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3.4.3. Expression of genes linked to regulatory phenotype during treatment 
RT-qPCR was used to evaluate the expression of FASL and IL5RA transcripts in B-cells from TB 
participants during treatment (diagnosis, month 2 and month 6). When the expression of genes 
were compared between the 3 time points, FASL expression was found to be significantly 
upregulated at month 6 compared to diagnosis (p=0.01; Figure 3.5a). Similarly, the expression of 
IL5RA was significantly upregulated at month 2 (p=0.01) and month 6 (p=0.01; Figure 3.5b) 

















Figure 3.4. Frequencies of Regulatory B-cells expressing CD40 and PD1 during treatment 
Pie charts depict frequencies of B-cells expressing either CD40, PD1 or both simultaneously in TB 
participants during treatment. Where BL is diagnosis, W2 is week 2, M1 is month1 and M6 is month 6 of 


































































Figure 3.5. Genes differentially expressed during anti-TB treatment 
Relative expression of genes as calculated using the delta-delta Ct method. Statistical differences 
calculated by means of Student t-test, where significant differences are indicated by an asterisk (* = p ≤ 0, 
05). Data represented as mean fold change with bars representing SEM. Positive values indicate increases 
in gene expression, and negative values indicate decreases in gene expression relative to diagnosis. 
 
 
3.4.4. Changes in BAL-secreted cytokines following anti-TB treatment but not in the 
plasma of TB cases 
The levels of 6 analytes (Granzyme-A, Granzyme-B, Perforin, sFasL, IL5 and GM-CSF) were 
measured in the BAL fluid and plasma of TB patients at diagnosis and at the end of treatment 
(EOT), as well as controls using Luminex technology. When comparing the analyte profiles 
measured at diagnosis and EOT in the BAL fluid of TB participants, we found that the profiles of 
the two different time points are different from each other (Figure 3.6a). Furthermore, the analyte 
profiles of BAL fluid of TB participants at both time points differed from that of CA controls 
(Figure 3.6a). When comparing the profiles in the plasma of these patients at diagnosis and EOT, 
no differences were seen (Figure 3.6b). Statistical analysis on the analyte levels in the BAL fluid 
of the TB patients and CTRLs revealed, that Granzyme-B (p<0.01) and Perforin (p<0.05) levels 
are significantly lower at EOT when compared to Dx (Figure 3.7b and d). EOT levels of 
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Granzyme-B (p<0.05), sFasL (p<0.01) and Perforin (p<0.05) were also significantly different 








Figure 3.6. Comparison of analyte levels in BAL and Plasma from TB cases at diagnosis and end of 
treatment 
Levels of the analytes in BAL and plasma are represented as percentages within the respective groups. (a) 
Analyte composition in BAL from TB cases at diagnosis (Dx) and end of treatment (EOT), and (b) Analyte 
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Figure 3.7. Comparison of analyte levels in BAL between Ctrls, TB participants at diagnosis and end 
of treatment. 
Analyte levels (pg/ul) were measured using LUMINEX analysis. ANOVA tests were performed to 
determine significant differences (p ≤ 0.05) between groups, which is indicated with an asterisk (*). (a) 
Granzyme A levels (b) Granzyme B levels (c) sFasL levels (d) Perforin levels (e) GM-CSF levels and (f) 






The aim of this study was to investigate whether the so-called regulatory “killer” B-cells are 
present during tuberculosis and the effects of treatment on the frequency of these cells. Literature 
indicates that these cells are present during autoimmune disease and may play an essential role in 
the regulation of inflammation [65], [66]. Furthermore, there are characteristics about the 
regulatory “killer” cells that lead us to think that these cells may play a role during tuberculosis 
as well, such as the induction of these cells by binding of M.tb CpG motifs to TLR9 [47]. 
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The phenotype of B-cells was assessed by means of flow cytometry to identify cells expressing 
FASL and IL5RA, which are markers associated with and used to identify killer B-cells [64]. 
Even though there were no significant differences, apart from the difference in the frequency of 
IgM- cells expressing IL5RA, the data suggests that there is a higher expression of FASL and 
IL5RA by cells from CTRLs compared to TB cases. Interestingly, there is an appearance of IgM- 
cells expressing both FASL and IL5Ra at month 1 of treatment, which increases by M6. The 
expression of FASL and IL5RA in IgM+ cells also increases during treatment, but appears earlier 
(week 2) during treatment. These results indicate the treatment may be inducing an increase in the 
expression of FASL by B-cells and that higher expression is associated with reversion back to 
healthy status, as the data shows that B-cells from healthy controls has a higher expression of 
FASL compared to TB cases at diagnosis 
To assess B-cell activation and exhaustion, we evaluated frequency of B-cells expressing CD40 
and PD1. IgM+ B-cells expressing CD40 increased over time, whereas IgM- B-cells expressing 
CD40 only started increasing by month 1 of treatment, with lower frequencies compared to IgM+ 
B-cells. This indicates that there is an increase in the activation of B-cells during treatment, which 
implies that treatment may be inducing activation of B-cells. Cliff and colleagues showed that B-
cell associated activity increases as treatment progresses [48]. 
To assess the effects of anti-TB treatment on the expression of FASL by B-cells at the gene level, 
we evaluated the changes in transcript levels over time. The results indicated that there is an 
increase in the levels of both genes by month 6 of treatment. These results correlate to the 
phenotypic results which indicates that there is an increase in the surface expression of FASL and 
IL5RA during treatment, even though those changes are not significant.  
As a representation of the site of infection, analyte levels in BAL was evaluated by means of the 
Luminex. sFasL increased by the end of treatment, whereas perforin and granzyme-B levels were 
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lower at the end of treatment. The increase in sFasL in BAL by the end of treatment also correlates 
to the phenotypic and gene expression results. FasL expression is mostly attributed to CD8+ T-
cells and NK cells in response to viral infections [67], [68]. Although B-cell frequencies in the 
lung is low, there is increased infiltration of B-cells into the lung during inflammation [69]–[72]. 
Thus, B-cells may also be contributing to the sFasL levels in the lung. 
Collectively, these results show that treatment induces an increase in the expression of FASL by 
B-cells. These results are in agreement with studies which show that there is an increase in 
expression of FASL by B-cells during parasitic infection and autoimmune disease [63], [73]. 
Lundy and colleagues (2001) show that B-cells from mice infected with Schistosoma mansoni had 
a higher expression of FASL compared to healthy mice [63]. Similarly, another study shows an 
increase in B-cell FASL expression during airway inflammation and asthma, as well as systemic 
lupus erythromatosis (SLE) [73]–[75]. Increased FASL expression by B-cells may have different 
effects, depending on the disease or infection. Culture experiments and killing assays carried out 
by Klinker and colleagues showed that B-cells stimulated with CD40L and IL5 induced FasL-
dependent apoptosis of CD4+ T-cells, and that these B-cells target T-cells based on the specificity 
of the antigen [64]. Thus, increased FASL expression may have a protective role in the case of 
autoimmune disease, where apoptosis of CD4+ T-cells leads to decreased inflammation. In 
contrast, apoptosis of Th1 cells may cause a skewed balance between Th1 and Th2 cells, leading 
to airway inflammation and asthma due to cytokines produced by Th2 cells.  
Here, the increase in the expression of FASL during treatment implies that these regulatory 
“killer” B-cells may play a protective role during TB. One hypothesis may be that these regulatory 
B-cells are inducing apoptosis of infected T-cells via FASL, as a means to rid the host of the 
bacteria. An alternative hypothesis may be that these regulatory B-cells are somehow inducing 
activation of T-cells, which later undergoes apoptosis [76], [77]. Literature states that FasL plays 
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a role during activation-induced cell death [76], [78]–[80]. When T-cells are activated, there is an 
increased expression of Fas by these cells and they become sensitized to FasL-induced apoptosis 
[79]. However, functional studies are required to further elucidate the role of the “killer” B-cells 
during TB.  
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Chapter 4. B- and T-cell interactions in the context of M.tb exposure 
 
4.1. Introduction 
Tuberculosis research has come a long way and studies focussing on how the host immune system 
responds to infection with Mycobacterium tuberculosis has indicated that T-cells are at the 
forefront of the fight against these invading pathogens. Several studies show that CD4+ T-cells 
correlate with disease progression and that cytokines produced by these cells are essential for the 
fight against M.tb [35], [36], [81]. More specifically, CD4+ T-cells that produce IFNγ, TNFα and 
IL2 simultaneously, have been associated with protection against M.tb [35].In contrast though 
some reports show that these multifunctional T-cells do not correlate with protection, but with 
disease (i.e. distinguish between TB cases and latent infection) [36]. 
Many factors are required for T-cell differentiation and homing to a specific lineage. For instance, 
antigen presentation cells (APCs) play a big role in T-cell behaviour, as well as the micro-
environment. If the micro-environment contains IL12, naïve T-cells will be induced to 
differentiate into the Th1 lineage and produce proinflammatory cytokines such as IFNγ, TNFα 
and IL2. Similarly, if the micro-environment contains IL4, naïve T-cells will differentiate into the 
Th2 lineage and produce anti-inflammatory cytokines such as IL4 [14]. 
As previously mentioned, APCs play a major role in T-cell activation and differentiation. T-cells 
require two signals for activation, one of which is provided by the APC. B-cells act as APCs as 
well, and are able to provide this costimulatory signal to T-cells for activation [12]. However, 
evidence exists that suggest that this is not the extent of the relationship between B- and T- cells, 
and that B-cells may further influence T-cell function, such as the frequency of effector and 
regulatory T-cells.  This may be by means of B-cell derived cytokines, or even surface factors 
[21], [22], [52], [82]. Studies indicate that B-cells play a role in the modulation of CD4+ T-cell 
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responses. This is mostly shown in the context of autoimmune disease and parasitic infections 
[82], [83]. Thus, the hypothesis of this study is that B-cells play a role in T-cell modulation during 
exposure/infection with BCG. The aim and objective of this study is to investigate how B-cells 
affect T-cell phenotype and function by co-culturing T-cells with autologous B-cells that have 
been stimulated under various conditions.  
 
4.2. Materials and Methods 
4.2.1. Ethics statement 
Ethical approval was obtained from the human research ethics committee (HREC) of Stellenbosch 
University and the City of Cape Town City Health (Ethics number N10/01/013). The study was 
conducted according to the Helsinki Declaration and International Conference of Harmonisation 
guidelines. Written informed consent was obtained from all study participants. 
 
4.2.2. Participant recruitment and sample collection 
For the purpose of this pilot study, 5 individuals with a QuantiFERON (QFN) positive status were 
recruited. These participants did not present any clinical symptoms of TB, and QFN status was 
indicative of exposure to M.tb. Additionally, 5 healthy individuals with a negative QFN status 
were recruited. All participants for this study were HIV negative.  
Peripheral blood (40ml) was collected from these individuals from which peripheral blood 
mononuclear cells (PBMCs) were isolated using the ficol-histopaque method. Subsequently, B-
cells were negatively isolated using MACS isolation kit II (Miltenyi Biotec, Germany) according 
to the manufacturer’s instructions. Additionally, T-cells were negatively isolated using the Pan T-
cells MACS isolation kit (Miltenyi Biotec) according to the manufacturer’s instructions.  
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4.2.3. B- and T-cell co-culture 
Purified B-cells were stimulated with BCG at a concentration of 1.25x106 CFU/ml (with or 
without other stimulants) in a 96-well round-bottom plate for three hours in an incubator at 37˚C 
and 5% CO2 in order to activate the cells. Further culture conditions are shown in Table 4.1. Where 
applicable, IL5 (Sigma, United States) was added at 50ng/ml and CD40L (Sigma, United States) 
at 2ug/ml. Subsequently, the cells were centrifuged at 1000rpm for 1 minute and supernatants 
were removed. Isolated T-cells were then added to the activated B-cells in a ratio of 2:1, and 
cultured in an incubator at 37˚C and 5% CO2 for 20hours. RPMI 1640 medium (Sigma, United 
States) was used for all culture conditions, supplemented with 10% L-glutamine. Following the 
incubation, the cultured cells were cryopreserved in 90% FCS 10% DMSO and placed in a Mr. 
Frosty overnight at -80˚C and transferred to liquid nitrogen the following day. 
 













1. T-cells only 
2. T-cells + BCG 
3. B-cells only 
4. B-cells + BCG 
5. B-cells + T-cells 
6. B-cells + BCG + T-cells 
7. B-cells + CD40L + IL5 
8. B-cells + CD40L + IL5 + T-cells 
9. B-cells + BCG + CD40L + IL5 + T-cells 
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4.2.4. B- and T-cell Flow Cytometry 
Cultured cells were retrieved from liquid nitrogen, quickly thawed and washed in FACS buffer 
containing PBS (Biowhittaker, Belgium)  and 2% heat-inactivated Fetal Calf Serum (FCS). The 
cells were then stained for 30 minutes with the following Beckton Dickenson (BD) antibodies for 
T-cell-specific analysis; CD3-FITC, CD4-HV500, CD8-APC-Cy7, CD25-PE, IFNg-PE-Cy7, 
TNF-APC, IL2-PerCP-CY5.5. Additionally, the following antibodies were used for B-cell-
specific analysis; CD19-BV510, CD3-PerCP, CD5-APC/Cy7, IgM-FITC, CD24-BV421 (all 
Identity Bioscience, South Africa), CD38-PE/Cy7, CD125 (IL5RA)-PE and CD178 (FASL)-APC 
(all Biocom Biotech, South Africa). Subsequently, the samples were acquired on a BD FACS 
Canto II and the data analysed using FlowJo v10 software. To determine the appropriate gating 
cut-off and to increase the accuracy of distinguishing different populations, Fluorescence-minus-
one (FMO) control samples were utilised (as described by Perfetto et al.(2004)) [84]. The 
background cytokine expression was subtracted from the T-cell stimulation conditions. The 
different gating strategies for B-cells and T-cell cytokine production can be found in Addendum 
B. 
 
4.2.5. Statistical Analysis 
Statistical differences between groups were calculated using the Mann Whitney U-test, and 
differences within groups were calculated using the Kruskal-Wallis with Dunns post-hoc tests. 
Spearman correlation tests were used for relationship analyses. Statistical significance is indicated 
by an asterisk (*), where p<0.05. Prism 6 Software (San Diego, CA) was used for all statistical 
analysis.  
 





4.3.1. Regulatory and Memory B-cell frequencies 
Evidence exist which indicate that regulatory B-cells (Bregs) suppress effector T (TE) cells during 
parasite infections and autoimmune disease [83]. Thus, to evaluate the changes in frequencies of 
Bregs in the context of M.tb exposure, we assessed the frequency of CD19+CD24hiCD38hi B-cells 
between QFN positive and negative groups, and in response to various stimuli. B-cells from QFN 
negative individuals had a higher frequency of Bregs compared to QFN positive individuals 
(Figure 4.1a). Similarly, when B-cells were stimulated with either BCG on its own or in 
combination with CD40L and IL5, there was a higher frequency of Bregs in QFN negative group 
compared to QFN positive (Figure 4.1a). These differences, however, were not significant.  
To evaluate changes in the frequency of memory B-cells (Bmemory), we assessed 
CD19+CD24hiCD38- B-cells. Overall, Bmemory frequencies were higher in the QFN positive 
group compared to QFN negative (Figure 4.1b). However, there were no significant differences 
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(a)                                                                (b) 
 
Figure 4.1. Changes in Frequency of Bregs and Bmemory cells.  
These cells are expressed as a percentage of CD19+ B-cells, where Bregs are CD19+CD24hiCD38hi and 
Bmemory are CD19+CD24hiCD38-. B-cells were either stimulated with BCG on its own or with CD40L 
and IL5. Statistical differences between groups were calculate using Mann Whitney U-test, and differences 
with in groups were calculated using Kruskal-Wallis with Dunns post-hoc tests. (a) Frequency of Bregs 
between QFN positive and negative groups following stimulation and (b) Frequency of Bmemory between 
QFN positive and negative groups after various stimulations. 
 
 
4.3.2. FasL-expressing B-cells 
Klinker and colleagues have shown that culturing naïve B-cells with CD40L and IL5 results in 
the expression of surface FasL (CD178) and IL5RA by B-cells, which they termed “Killer” B-
cells [64]. In order to assess this expression in the context of M.tb exposure, we stimulated B-cells 
from QFN negative and positive individuals with BCG on its own, and in combination with 
CD40L and IL5. To evaluate the frequency of these “Killer” B-cells, we assessed 
CD19+CD5+IgM+CD38+ B-cells. Within the QFN positive group, there was a significant increase 
in the frequency of “Killer” B-cells (CD178+IL5RA+) following stimulation (p=0.039, Figure 
4.2a). There were no significant differences in the frequency of B-cells expressing CD178 only 
(CD178+IL5RA, Figure 4.2b). However, culturing B-cells with CD40L and IL5 resulted in an 
increase in the frequency of CD178+ B-cells compared to B-cells only within the QFN negative 
group. Similarly, stimulation of B-cells with CD40L and IL5 resulted in a significant increase in 
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the frequency of CD178-IL5RA+ B-cells (p=0.023, Figure 4.2c). Furthermore, even though not 
significant, CD40L and IL5 stimulation induced a higher frequency of CD178-IL5RA+ B-cells in 
both QFN negative (ns, p>0.05) and positive groups (ns, p>0.05), compared to B-cells only.  
 
Figure 4.2. Changes in frequency of FasL-expressing B-cells 
These cells are expressed as a percentage of CD19+CD5+ B-cells. B-cells were either stimulated with BCG 
on its own or CD40L and IL5. Statistical differences between groups were calculate using Mann Whitney 
U-test, and differences with in groups were calculated using Kruskal-Wallis with Dunns post-hoc tests. 
Significant difference is indicated by an asterisk (*) (a) Frequency of CD178+IL5RA+ B-cells between 
QFN positive and negative groups after various stimulations (b) Frequency of CD178+IL5RA- B-cells (c) 
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4.3.3. Effector and Regulatory T-cells 
T-cells are essential in the immune response against M.tb infection, and there is evidence that B-
cells may modulate T-cell phenotypes. Thus, we assessed the phenotype of T-cells following 
culture with B-cells that have been stimulated under various conditions. More specifically, we 
evaluated the frequencies of CD3+CD4+CD25+ effector T-cells (TEs) and CD3+CD4+CD25hi 
regulatory T-cells (Tregs). 
After T-cells were cultured with B-cells stimulated with BCG, there was a decrease in TEs in both 
QFN negative and positive groups, compared to T-cells on its own (Figure 4.3a). This was, 
however not a significant difference. Similarly, there was a significant decrease in the frequency 
of TEs in the QFN negative group when T-cells were cultured with B-cells stimulated with BCG, 
CD40L and IL5 (p=0.01, Figure 4.3a).  
After T-cells were cultured with B-cells that was stimulated with BCG, there was a decrease in 
Tregs in both QFN negative and positive groups (Figure 4.3b) compared to T-cells cultured on its 
own. Similarly, when T-cells were cultured with B-cells that were stimulated with CD40L and 
IL5, there was a decline in the frequency of Tregs in both QFN negative and positive groups. Treg 
frequency in the QFN negative group was also lower after being cultured with B-cells stimulated 
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Figure 4.3. Changes in the frequency of TE and Treg cells 
These cells are expressed as a percentage of CD3+ T-cells. T-cells were cultured on its own, or with B-
cells that were either stimulated with BCG on its own or CD40L and IL5. Statistical differences between 
groups were calculate using Mann Whitney U-test, and differences with in groups were calculated using 
Kruskal-Wallis with Dunns post-hoc tests. Significant difference is indicated by an asterisk (*) (a) 
Frequency of CD3+CD4+CD25+ T-cells between QFN positive and negative groups after various 
stimulations (b) Frequency of CD3+CD4+CD25hi T-cells  
 
 
4.3.4. Relationship between Bregs and Tregs 
Studies show that when Bregs are induced, these cells suppress TEs and induce Tregs. Thus, to 
evaluate whether this relationship applies in the context of M.tb exposure, we assessed the 
correlation between Bregs and TE, as well as Bregs and Tregs. 
There was a positive correlation between Bregs and TEs from QFN positive individuals when B-
cells were stimulated with CD40L and IL5 (r=0.97, p=0.03, Figure 4.4e). Furthermore, there was 
a positive correlation between Bregs and Tregs from QFN positive individuals after B-cells were 
stimulated with CD40L and IL5 (r=0.97, p=0.03, Figure 4.5e). 




Figure 4.4. Correlation between frequency of Breg and TE cells 
Spearman correlation analysis of Bregs and TEs in both QFN positive and negative groups. (a) Correlation 
between Bregs and TE when QFN positive B-cells cultured with B-cells (b) Correlation between Bregs 
and TE when QFN negative B-cells cultured with B-cells (c) Correlation between Bregs and TE when T-
cells were cultured with BCG-infected B-cells from QFN positive individuals. (d) Correlation between 
Bregs and TE when T-cells were cultured with BCG-infected B-cells from QFN negative individuals (e) 
Correlation between QFN positive Bregs and TE when T-cells cultured with B-cells stimulated with 
CD40L and IL5 (f) Correlation between QFN negative Bregs and TE when T-cells cultured with B-cells 
stimulated with CD40L and IL5. 





Figure 4.5. Correlation between Frequency of Breg and Treg cells 
Spearman correlation analysis of Bregs and Tregs in both QFN positive and negative groups. (a) 
Correlation between Bregs and Tregs when QFN positive B-cells cultured with B-cells (b) Correlation 
between Bregs and Tregs when QFN negative B-cells cultured with B-cells (c) Correlation between Bregs 
and Tregs when T-cells were cultured with BCG-infected B-cells from QFN positive individuals. (d) 
Correlation between Bregs and Tregs when T-cells were cultured with BCG-infected B-cells from QFN 
negative individuals (e) Correlation between QFN positive Bregs and Tregs when T-cells cultured with B-
cells stimulated with CD40L and IL5 (f) Correlation between QFN negative Bregs and Tregs when T-cells 
cultured with B-cells stimulated with CD40L and IL5. 
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4.3.5. T-cell cytokine production 
B-cells produce cytokine which in turn may affect T-cell cytokine production [82]. Thus, in order 
to investigate the effect of B-cell phenotype on T-cell cytokine production, we evaluated CD4+ 
and CD8+ T-cell cytokine production following culture with pre-stimulated B-cells.  
B-cells from QFN positive individuals that have not been pre-stimulated induced an increase in 
IL2-producing CD4+ T-cells, as well T-cells that produce both IFNγ and IL2 (ns, p>0.05, Figure 
4.6a). B-cells that have been pre-stimulated with BCG induced a similar cytokine milieu to 
unstimulated B-cells, with the addition of CD4+ T-cells that produce IFNγ and IL2 (ns, p>0.05). 
Reports suggest that B-cells stimulated with CD40L and IL5 induced FasL-expressing B-cells 
[64]. Thus, in order to see the effect of these FasL-expressing B-cells on T-cell cytokine 
production, we cultured T-cells with B-cells pre-stimulated with CD40L and IL5. When BCG-
infected B-cells were stimulated with CD40L and IL5 (i.e. induce FasL expression), there was an 
increase in CD4+ T-cells that produce IFNγ (ns, p>0.05). 
Unstimulated B-cells from QFN negative individuals induced an increase in CD4+ T-cells that 
produce TNFα, IFNγ and TNFα, IFNγ and IL2, and TNFα and IL2 (ns, p>0.05, Figure 4.6b). 
Following BCG infection, the B-cells induced CD4+ T-cells that produce IFNγ and IL2, and IL2 
only (ns, p>0.05). When BCG-infected B-cells were stimulated to induce FasL, this cytokine 
milieu changes, where CD4+ T-cells are induced to produce IL2 only, IFNγ and IL2, and IFNγ 













Figure 4.6. Cytokine production by CD4
+
 T-cells 
Change in cytokine production by CD4+ T-cells following various stimulation conditions with B-cells 
compared to T-cells by itself. T cells only represent background cytokine production, which were 
subtracted following the different stimulations. The key indicates which cytokine combinations the colours 
represent. (a) Cytokine production in QFN positive group (b) Cytokine production in QFN negative group. 
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Furthermore, CD8+ T-cell cytokine production was evaluated in response to the various culturing 
conditions. Unstimulated B-cells from QFN positive individuals did not induce any change in the 
CD8+ T-cell cytokine milieu (ns, p>0.05, Figure 4.7a). However, when these B-cells were 
stimulated with BCG, it induced CD8+ T-cells that produce TNFα, TNFα and IL2, and IFNγ and 
TNFα (ns, p>0.05). Furthermore, following the pre-stimulation of BCG-infected B-cells with 
CD40L and IL5, there was an increase in CD8+ T-cells producing IL2 only, TNFα only, TNFα 
and IL2, as well as multi-functional CD8+ T-cells (ns, p>0.05).  
Unstimulated B-cells from the QFN negative group induced an increase in CD8+ T-cells that 
produce IFNγ and TNFα, IL2 only, and IFNγ and IL2 (ns, p>0.05, Figure 4.7b). When B-cells 
were stimulated with BCG, it induced an increase in CD8+ T-cells that produce TNFα only, and 
TNFα and IL2 (ns, p>0.05). Furthermore, when BCG-infected B-cells are stimulated to express 
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Figure 4.7. Cytokine production by CD8
+
 T-cells 
Change in cytokine production by CD8+ T-cells following various stimulation conditions with B-cells 
compared to T-cells by itself. T cells only represent background cytokine production, which has already 
been subtracted following the different stimulations. The key indicates which cytokine combinations the 
colours represent. (a) Cytokine production in QFN positive group (b) Cytokine production in QFN 
negative group. 




The aim of this study was to assess how B-cells influence T-cell phenotype and cytokine 
production in the context of M.tb exposure. For the purpose of this study, QFN positive individuals 
who represent healthy exposed (i.e. latent TB infection) and QFN negative who represent healthy 
uninfected individuals were used. All these participants were HIV negative. The difference 
between QFN positive individuals and TB cases is that the immune system of QFN positive 
individuals were able to contain M.tb infection and did not develop active TB disease. Thus, 
understanding the relationship between B- and T-cells in QFN positive individuals is essential, in 
order to understand how these cells contribute to overcoming the infection.  
Evidence exist that suggest that B-cells may influence T-cell effector functions by means of 
cytokine production and various phenotypes such as regulatory and FasL-expressing B-cells [21], 
[22], [52], [82]. Thus, the objectives here were to assess B- and T-cell phenotypes, as well as T-
cell cytokine production in response to various stimuli in the context of M.tb exposure.  
 
To assess B-cell phenotypes in the context of M.tb exposure, and how it compares to healthy 
individuals, the frequency of regulatory and memory B-cells were evaluated. There were no 
significant changes in the frequency of regulatory B-cells (Bregs) when stimulated with BCG or 
CD40L and IL5. Although, Bregs frequencies were higher in QFN negative individuals compared 
to QFN positive individuals (not significant). These CD19+CD24hiCD38hi Bregs have not yet been 
investigated during M.tb infection or disease. Wang and colleagues (2015) show that these cells 
are functional during gastric cancer [25]. However, they show that there is no significant 
difference in the frequency of Bregs between healthy individuals and those with cancer [25]. 
Furthermore, Joosten and colleagues (2016) showed that the frequency of Bregs are slightly higher 
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in healthy individuals compared to individuals with latent TB infection, even though this was not 
statistically significant [85]. This is similar to the results in the current study.  
Additionally, the frequency of “killer” B-cells was investigated. The results show that there was 
an increase in the frequency FASL+IL5RA+ “killer” B-cells when stimulated with either BCG or 
CD40L and IL5 from both QFN positive and negative groups, even though it lacks statistical 
significance. These FasL-expressing B-cells have not yet been investigated in the context of M.tb 
infection or disease, but rather during autoimmunity and parasite infections. These studies show 
that there is an increase in the frequency of these FasL-expressing B-cells, which in turn have a 
beneficial impact as it has a regulatory effect on proinflammatory responses [43], [44], [58], [60]. 
In part, the results from the current study may indicate a beneficial role for FasL-expressing B-
cells due to the increased frequency following BCG stimulation. As discussed in chapter 3, we 
hypothesise that FasL-expressing B-cells may be inducing FasL-mediated apoptosis of CD4+ T-
cells or inducing activation of T-cells which later leads to apoptosis due to increased Fas 
expression by these activated T-cells. Furthermore, results from chapter 3 showed that the control 
group (LTBI) had a higher expression of FasL compared to TB cases, and anti-TB treatment 
induced increased expression of FasL in TB cases.  
 
In order to investigate the effect B-cells have on T-cells function, the frequency of effector (TE) 
and regulatory (Treg) T-cells was evaluated following culturing with B-cells that have been pre-
stimulated in various ways. B-cells induced an increase in the frequency of TEs in QFN positive 
individuals, even though this is not a significant change. This may imply that B-cells contribute 
to T-cell effector functions by inducing an increase in TEs. B-cells may be producing cytokines 
that enhances T-cell responses, as proposed by Lund and colleagues (2010) [83]. Here, the fact 
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that B-cells (unstimulated) from QFN positive individuals having the ability to induce an increase 
the frequency of TEs is interesting as these individuals have been exposed to M.tb but did not go 
on to develop TB disease. Could the B-cells contribution have enhanced protection against M.tb 
infection? Further experiments and over a longer follow up period are required to elucidate this 
phenomenon/hypothesis/question.  
In contrast, culturing BCG-infected B-cells and B-cells that have been induced to express FasL, 
with T-cells resulted in a decline in the frequency of TEs (not significant). Stimulating B-cells 
with CD40L and IL5 induces FasL-expressing B-cells, which is a subset of Bregs. Studies show 
that these FasL-expressing cells are able to produce IL10 as well, as a means to regulate immune 
responses. Literature indicates that Bregs suppress TEs by means of producing cytokine such as 
IL10 or FasL-mediated apoptosis, which supports the results shown here [25], [64].  
As previously mentioned, Bregs induces Tregs during autoimmune disease, and suppresses TEs 
[25], [83]. Here, the correlation analysis indicate that there is a positive relationship between Bregs 
and Tregs. Similarly, there is a positive correlation between Bregs and TEs as well. These results 
are only supported in part by literature[25], [83], where one would expect a positive relationship 
between Bregs and Tregs. In contrast to the results here, one would expect a negative correlation 
between Bregs and TEs, as literature suggests that TEs should decrease with an increase in Bregs.  
The increase in frequency of Tregs have different effects, depending on the stimulation condition. 
For instance, during autoimmune diseases, it suppresses/dampens the inflammatory responses by 
effector T-cells but during TB disease it may have a detrimental effect [26], [27], [83], [86], [87]. 
Murine studies have shown that depletion of Tregs in mice which have been infected with M.tb 
displayed better clearance of bacteria, and that enhanced Treg frequencies led to increased 
bacterial load [86], [87]. Further studies indicated that Tregs from individuals with active TB 
Stellenbosch University  https://scholar.sun.ac.za
65 
 
disease dampen T-cell responses to M.tb antigen [26], [27]. The latter effects are mostly attributed 
to CD4+CD25hiFoxP3+ Tregs, whereas the current study focussed on CD4+CD25hi Tregs.  
 
Finally, in order to assess the effect of B-cells on T-cell cytokine production, autologous B- and 
T-cells were co-cultured and CD4+ and CD8+ responses were measured. Despite the statistical 
insignificance of the results, it implies that B-cells, whether pre-stimulated or not, are able to 
induce cytokine production by both CD4+ and CD8+ T-cells. These results are in agreement with 
Soares et al (2008) who showed that stimulating blood with BCG induces complex cytokine 
profiles in T-cells (i.e. combinations of IFNγ, IL2 and TNFα) [88]. Here, B-cells, depending on 
the antigen or microenvironment, may be secreting cytokines that influence T-cell cytokine 
production [83], or it may be through contact with B-cells that influenced cytokine production by 
T-cells. Further experiments are required to elucidate this phenomenon. 
Cytokine production by CD4+ T-cells in the context of TB disease has received much more 
attention than CD8+ T-cells. Our results indicate that B-cells induce cytokine production by CD4+ 
T-cell as well as CD8+ T-cells in both M.tb exposed and unexposed individuals. Researchers have 
been sceptical about CD8+ T-cells role during TB disease because of the manner in which antigens 
are presented to these cells. CD8+ T-cells recognise antigen in the context of MHC I, which is 
loaded in the cytosol [89]. Thus, because M.tb is phagocytosed/endocytosed, one would expect 
that these peptides may only be presented in the context of MHC II and thus CD4+ T-cell responses 
have been the main focus. However, there is evidence that CD8+ T-cells play a role during active 
TB [90], but further studies are required to confirm this in human. Furthermore, there is evidence 
which suggests that CD8+ T-cells are required for the control of M.tb  infection in latently infected 
mice [91]. A possible reason for the CD8+ T-cell response is the translocation of the phagosome 
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to the cytosol, which then leads to peptides being loaded onto MHC I [92], and cross-presentation 
of peptides to MHC I may occur when dendritic cells take up apoptotic vesicles from infected 
macrophages [93]–[95].  
 
What is the significance of these results? If B-cells have the ability to induce cytokine production 
by CD8+ T-cells, then it may induce the production of cytokines and other cytotoxic factors by 
these cells as well. This would serve as a means to target infected cells to rid the host of the 
invading pathogens [96]. Vaccines are commonly targeted in a manner which enhances T-cell 
responses to M.tb infection [88], [97]. However, vaccines that target CD8+ T-cell responses are 
now being considered as well [96]. Thus, if B-cells are able to induce cytokine production by 
CD8+ T-cells, or CD4+ T-cells, then vaccines can be designed to target B-cells so as to indirectly 
enhance cytokine production by both CD4+ and CD8+ T-cells. Similarly, once the role of Bregs 
have been elucidated, including FasL-expressing B-cells, perhaps these cells could also serve as 
a target for vaccines in order to enhance T-cell responses.  
 
Collectively, these results show that B-cells play a role in modulating T-cell behaviour, whether 
it be the T-cell phenotypes or effector cytokine production. These results are only preliminary and 
have a few limitations, including the small sample size and the absence of an active TB disease 
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Chapter 5. Discussion 
 
TB disease represents a spectrum which include a healthy infected state without the presentation 
of symptoms (i.e. latent TB infection), and TB disease with symptoms [98]. Much research has 
gone into understanding how the host immune system responds to invasion by M.tb, and how the 
immune system fights the invasion. However, one has to take into account the different phases of 
disease in order to understand why some people’s immune system can contain the infection and 
others cannot.  These phases include the innate immune phase, during which macrophages are 
infected with M.tb, followed by the adaptive immune phase, during which cell-mediated immunity 
is initiated through presentation of antigen to T-cells. At this stage, the immune system can either 
contain the infection, which is termed the quiescent phase or latent infection, or the infection can 
develop into an active replicating phase which is TB disease [99]. In order to fully understand the 
multitude of ongoing processes that lead to control of infection or the establishment of 
immunopathology, or at least attempt to, the focus should be on every aspect of the immune 
system such as the different immune cells and how they differ in phenotype and function during 
the different disease states and how it compares to that of uninfected (and exposed) healthy 
individuals. For the purpose of the study, B- and T-cells were the focus of this study from cohorts 
which included TB cases followed up throughout treatment, healthy uninfected and healthy 
infected individuals (latent infection), as well as other lung disease controls. The aims of the study 
was to a) evaluate how B-cells regulate their genes/receptor repertoire during M.tb 
infection/exposure and how this is affected by anti-TB treatment and b) to investigate how B-cells 
modulate T-cell behaviour in latently infected individuals compared to healthy uninfected 
individuals. T-cells, according to research, are at the forefront of the defence against infection 
with M.tb. Some say that multifunctional CD4+ T-cell responses correlate with protection against 
infection [35], [100], whereas others disagree [101]. On the contrary, B-cells have not been of any 
Stellenbosch University  https://scholar.sun.ac.za
68 
 
significance in the defence against M.tb. Research of B-cells during TB show that humoral 
responses may enhance protection by improving killing by phagocytes, but is not essential for 
protection [102]–[104]. However, as the understanding of B-cell development has progressed, it 
is apparent that B-cell function extends beyond antibody production and antigen presentation. 
Additional functions include cytokine production and various regulatory phenotypes [20], [21], 
[83].  Therefore, we proposed that B-cells have the potential to influence T-cell behaviour. 
In order to address the first aim, transcriptional and phenotypic analysis was utilised. 
Transcriptional analysis is useful for several reasons including biological discovery, as well as 
identifying biomarkers [48], [49], [51]. Evaluating the levels of specific genes expressed by 
immune cells gives insight into particular functions of the cells [48], [49]. Furthermore, one can 
utilise phenotypic analysis for biological discovery at the protein level, as a means to confirm 
results from transcriptional analysis (gene level). Cohorts used for this part of the study included 
healthy controls with a QFN positive status which is indicative of latent TB infection (LTBI), as 
well as TB cases who were followed up at various time points throughout anti-TB treatment. In 
addition, a group of participants with other lung diseases were included as controls. These 
participants were recruited from areas to which TB is highly endemic, and where more than the 
chances of individuals having been exposed to M.tb is high. Prevalence rates in these areas have 
been reported as high as 1000/100 000 [105]. 
The present study had some shortcomings, including small cohort sizes and cohorts recruited  
mainly from one area  (even though high burdened) which should be addressed in future studies; 
drawing conclusions from these results could lead to over interpretation of significance. 
Furthermore, the co-culture experiments were only carried out using QFN positive and negative 
individuals. Although this pilot study represents the first attempt at understanding the complex 
interactions between B-cells and T-cells in a non-diseased state it would be important to include 
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newly diagnosed, untreated TB cases and follow them up from diagnosis to successful treatment, 
as well as other lung disease controls in order to understand the dynamics of the interaction during 
active disease states.  
 
Firstly, the results from the transcriptional analysis of B-cells from healthy controls and TB cases 
showed that B-cell genes which is indicative of activation, such as CD19 and APRIL was increased 
by the end of treatment. These results fit in with a previous report from our group that indicated 
circulating marginal zone and memory phenotypes of B-cells differ between pre-TB treatment 
and at the end of TB treatment. That study also found that a sub-population of activated memory 
B-cells (CD19+IgM+CD23+CD27+) are present at the end of successful TB treatment [106]. This 
result was confirmed by phenotypic analysis of B-cells from healthy controls and TB cases 
followed up during treatment in the current study. The frequency of B-cells expressing CD40 
receptor increased during treatment, which is indicative of B-cell activation. B-cells require two 
signals for activation, one of which is B-cell receptor ligation and the second signal being ligation 
of CD40 by CD40 ligand (CD40L) [16]. Therefore, when CD40 ligates, the cell upregulates the 
expression of CD40 for maximum ligation/activation. These results are in line with a study by 
Cliff and colleagues (2013) which indicated that there were increased expression of IgM, IgD as 
well as CD19, later during treatment as shown by transcriptional analysis [48]. This suggests that 
B-cells are either depleted in the periphery, or that gene expression is altered during TB disease. 
Thus, our results indicate that anti-TB treatment is inducing B-cell activation as a means to restore 
the immune system. B-cells may be using the production of antibody to opsonize and in turn 
enhance phagocytosis, activate complement components (C1q and C2) or the B-cells may be 
producing cytokines that further enhance cell-mediated immune responses against M.tb [107], 
[108]. Generally, it is understood that antibodies mostly protect against extracellular pathogens, 
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but evidence exists which suggests that antibodies have the potential to protect against 
intracellular pathogens such as Leishmania species and Plasmodium berghei [109], [110]. 
As previously mentioned, B-cells possess non-humoral functions as well, which includes the 
production of cytokines. Additionally, there are small subsets of B-cells that are being discovered 
including regulatory B-cells (Bregs) which produce cytokine such as IL10 and express death-
inducing markers such as FasL [64]. These Bregs are mostly researched during autoimmune 
disease, but evidence lead us to believe that these Bregs may be active during TB as well. 
The results from transcriptional and phenotypic analyses showed that B-cell regulatory functions 
are enhanced during anti-TB treatment. This is indicated by the increase in the expression of FASL 
and IL5RA, which are genes associated with a small subset of FasL-expressing regulatory B-cells 
[64]. This finding was confirmed by phenotypic analysis of B-cells from TB cases at diagnosis 
and throughout treatment, where the results indicate that there is an increase in the frequency of 
B-cells expressing FASL and IL5RA by the end of treatment. To further confirm this increase in 
expression of FasL, BAL fluid from TB cases during treatment and controls was analysed by 
means of Luminex technology. This serves as a proxy for the site of infection. The results showed 
that there was an increase of sFasL in the lung of TB cases at the end of treatment. Although one 
cannot directly conclude that the B-cells in the lung are producing the sFasL, literature does 
suggest that there is an infiltration of B-cells into the lung during inflammation [69]–[72]. Thus, 
B-cells are potentially contributing to the sFasL levels in the lung. Collectively, these result 
indicate that anti-TB treatment boosts B-cell activation, as well as Breg activity. More 
specifically, there is an increase in the activity of killer B-cells. These CD19+IgM+ FasL-
expressing B-cells have been studied during autoimmune disease and parasite infections, and the 
results showed that these cells are induced by stimulation with CD40L and IL5, and that it induces 
FasL-mediated apoptosis of CD4+ T-cells [64]. These cells may have a protective or detrimental 
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role depending on the disease condition. For instance, during autoimmune disease, apoptosis of 
CD4+ T-cells reduces auto-inflammation. In contrast, apoptosis of Th1 cells may cause a skewed 
balance between Th1 and Th2 cells, leading to airway inflammation and asthma due to cytokines 
produced by Th2 cells. In the current study, however, the increased expression of FasL during 
successful anti-TB treatment implies that these FasL-expressing B-cells may have a protective 
role. One hypothesis is that these cells may be inducing apoptosis of infected T-cells as a means 
to clear bacterial infection, or they may be inducing activation of T-cells which subsequently lead 
to apoptosis (Figure 5.1). The latter hypothesis has been termed activation-induced cell death [77], 
[111]. Further studies are required to elucidate this phenomenon.  
 
Figure 5.1. Proposed effect of FasL-expressing B-cells during active TB disease 
The diagram represents possible interaction scenarios between FasL-expressing B-cells and T-cells. There 
is an increase in the expression of FasL mRNA and surface-expressed FasL by the end of anti-TB 
treatment, where Dx is at diagnosis and M6 is end of treatment. A proposed hypothesis for the effects of 
these B-cells is: (a) B-cells directly induce FasL-mediated apoptosis of T-cells or (b) T-cells may undergo 
activation, where 1 represents TCR ligation and 2 is co-stimulation, which leads to an increase in the 
expression of Fas by T-cells. Thus, making them susceptible to FasL-mediated apoptosis.  
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Seeing that B-cells have these additional functions, we hypothesised that the extent of the 
relationship between B- and T-cells spreads beyond providing co-stimulatory signals to one 
another via co-stimulatory molecules that are expressed by the respective cells. In order to 
investigate this extended relationship, autologous B- and T-cells from M.tb exposed and 
unexposed (as defined by QFN status) individuals were co-cultured under different antigenic 
conditions. Subsequently, B-cell phenotypes were assessed, as well as T-cell phenotypes and 
cytokine production by means of flow cytometry.  
Breg frequencies were higher in QFN negative individuals compared to QFN positive individuals, 
but not significantly higher. As previously mentioned, another Breg subset exists that expresses 
FasL and induces apoptosis of CD4+ T-cells. Here, we found that BCG in combination with 
CD40L and IL5 induces an increase in the frequency of FasL-expressing B-cells.  
Assessing Treg frequencies showed that B-cells that were stimulated with BCG, and CD40L and 
IL5, induced a decrease in the frequency of Tregs in both M.tb exposed and unexposed. 
Furthermore, unstimulated B-cells induced an increase in the frequency of TEs in M.tb exposed 
individuals. On the contrary, B-cells stimulated with BCG, and CD40L and IL5, induced a 
decrease in the frequency of TEs from M.tb exposed individuals. The decline in TEs may be due 
to the increase in FasL-expressing cells, as Klinker and colleagues also showed that these FasL-
expressing B-cells induce apoptosis of CD4+ T-cells [64]. 
Research shows that Bregs induce Tregs and suppress TEs during autoimmune disease [83]. Thus, 
this relationship between Bregs, Tregs and TEs was assessed in the current study. There was a 
significant positive correlation between Bregs and Tregs from M.tb exposed individuals that have 
been stimulated with CD40L and IL5. Similarly, there was a significant positive correlation 
between Bregs and TEs from M.tb exposed individuals that have been stimulated with CD40L 
and IL5 (Figure 5.2). However, this differs from the proposed negative relationship between Bregs 
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and TEs. This may be because of the different conditions (i.e. M.tb exposure vs autoimmune 
disease), or it may be due to the small number of participants analysed as part of the current study. 
Furthermore, the significant correlations in only M.tb exposed individuals implies that prior or 




Figure 5.2. Proposed relationship between Bregs, Tregs and TEs during LTBI 
The diagram represents a proposed relationship based on the results from the current study. The correlation 
results imply that antigen activated CD19+CD24hiCD38hi Bregs induce CD4+CD25hi Tregs as well as 
CD4+CD25+ TEs. Where Ag (red) is antigen, Bregs (blue) is regulatory B-cells, Tregs (yellow) is 
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The enhancement of Tregs have different effects, depending on the condition. For instance, if 
Tregs are enhanced during autoimmune diseases, it suppresses or dampens the inflammatory 
responses by effector T-cells [83]. However, during TB disease, enhanced Treg frequencies may 
have a detrimental effect. A murine study has shown that depletion of Tregs in mice which have 
been infected with M.tb displayed better clearance of bacteria [86]. Further studies indicated that 
Tregs from individuals with active TB disease dampen T-cell responses to M.tb antigen [26], [27]. 
A study by Shafiani and colleagues (2010) further confirmed that there is an increased bacterial 
load in mice when there is enhanced Treg frequencies, and attributed this to Tregs’ ability to delay 
effector T-cells to migrate to the lung [87]. The latter effects are mostly attributed to 
CD4+CD25hiFoxP3+ Tregs, and the current study focussed on CD4+CD25hi Tregs. Further studies 
are required to confirm whether these cells are the same.  
 
Assessing cytokine production by CD4+ and CD8+ T-cells indicated that B-cells on its own, or 
following stimulation with BCG, and CD40L and IL5, are able to induce cytokine production by 
both T-cell phenotypes. These results are from healthy individuals who have either been exposed 
to M.tb or not. It is important to know what occurs in a “healthy” state, so that one can understand 
how the immune system resists or contains infection by invading pathogens. Here, studying the 
immune response of latently infected/exposed individuals is essential, as most of the population 
are latently infected. Also, prior work from our group on individuals from the same high TB 
burden area showed that B-cells are able to produce cytokine in response to BCG stimulation or 
TLR9 activation in latently infected/exposed individuals [106]. The cytokine production was 
mostly attributed to B-cells with a plasmablast (CD138+) phenotype [112]. Similarly, Bermejo 
and colleagues identified B cells with a plasmablast phenotype as a major source IL17 production 
in response to Trypanosoma cruzi infection [29].  
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Collectively, the results imply that B-cells affect T-cell phenotype and function. However, the 
questions remain: why are these results significant or what impact will the knowledge of B-cell 
function have on TB research? This is important, because most vaccines are aimed at enhancing 
T-cell responses in order to improve protection against M.tb infection [97], [113]. If TB vaccines 
are aimed at enhancing T-cell responses, then these results offer a potential alternative to inducing 
or enhancing T-cell responses. Here, the results indicate that B-cells also induce cytokine 
production by CD4+ T-cell as well as CD8+ T-cells. This is interesting as Pinxteren and colleagues 
(2000) found that CD8+ T-cells are required for the control of M.tb  infection in latently infected 
mice [91]. There is also evidence that CD8+ T-cells play a role during active TB [90], but further 
studies are required to confirm this in humans. Thus, if B-cells are able to induce cytokine 
production by CD8+ T-cells, then perhaps it may induce the production of cytokines and other 
cytotoxic factors by these cells as well. This would serve as a means to target infected cells to rid 
the host of the invading pathogens [96]. Similarly, once we have further elucidated the role of the 
FasL-expressing B-cells, and why exactly they are being induced during treatment, one could aim 
to improve current treatment regimens to further enhance the frequency of these B-cells, or design 
a vaccine that targets FasL-expressing B-cells in order to protect against M.tb infection.  
Additional studies are clearly required to further elucidate the relationship between B- and T-cells, 
and how exactly B-cells are inducing T-cell responses, and to what extent the responses would be 
beneficial. For instance, are B-cells using cytokines (e.g. IFNγ or IL10), surface molecules (e.g. 
FasL) or a combination of both to modulate T-cells responses? Also, more understanding of 
signalling pathways leading to B-cell activity are required. For instance, transcriptional analysis 
from the current study indicated an increase in the expression of APRIL. Is this a potential target 
for a vaccine or treatment? Enhancing the expression of APRIL may enhance B-cell activation 
and subsequent effector functions. Once we have a better understanding of this, vaccines may be 
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designed to target B-cells in a manner so as to indirectly modulate CD4+ and CD8+ T-cell 
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Table A1. Demographics of Cohort used for B-cell phenotypic analysis 
 
Table A2. Demographics of Cohort used for Gene expression analysis 
 TB CTRL OLD 
No. of Females  8 10 5 
No. of Males 12 0 5 
Median Age (years old) 28 24 37 
QuantiFERON status (Dx) NA POSITIVE 5 POSITIVE 
5 NEGATIVE 
Sputum-culture status (Dx) POSITIVE NEGATIVE NEGATIVE 
 
Table A3. Demographics of Cohort used Luminex analysis 
 TB (Dx) CA  TB (M6) 
No. of Females 4 7 9 
No. of Males 4 3 11 
Median Age 41 60 31 
Gene Xpert/Sputum-culture  POSITIVE NEGATIVE NEGATIVE 
 
 
 TB CTRL 
No. of Females 2 10 
No. of Males 11 5 
Median Age (years old) 50 38 
Gene Xpert-MTB/RIF Assay POSITIVE NEGATIVE 
QuantiFERON status NA POSITIVE 
Sputum-culture status (Dx) 3 NEGATIVE NA 
10 POSITIVE 






Figure B1. Gating strategy for identifying Breg and Bmemory cells.  
Single cells were gated to exclude doublets, and subsequently lymphocytes were gated on SSC and FSC. 
CD19+ B-cells were included in order to identify CD24hiCD38hi Bregs and CD24hiCD38- Bmemory cells. 





















Figure B2. Gating strategy used to identify FasL-expressing B-cells 
To identify FasL-expressing B-cells, lymphocytes were gated on SSC and FSC. CD3- lymphocytes were 
included for further analysis. Subsequently CD19+CD5+ B-cells and IgM+CD38+ cells were gated in order 
to assess the expression of CD178 and IL5Ra. The cut-off values were obtained using stimulated T-cells 



















Figure B3. Gating strategy used to identify Treg and TE cells 
To identify Tregs and TEs, lymphocytes were gated on SSC and FSC and CD3+ lymphocytes were included 
for further analysis. Subsequently CD4+CD25+ TEs and CD4+CD25hi Tregs were gated. The cut-off values 













 T-cell cytokines 
To identify cytokine-producing T-cells, lymphocytes were gated on SSC and FSC. CD3+ lymphocytes 
were included for further analysis. Subsequently, CD4+ and CD8+ T-cells producing different combinations 
of IFNγ, TNFα and IL2 were gated. The cut-off values were obtained using stimulated T-cells from 
PBMCs.  
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